Gerald Ho, MD
Rheumatology · la Palma, CANPI 1205833662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Amgen at 35.2% of the total. Reporting peaked in 2019 at $3,137 and has fallen 97.3% since, to $86 in 2025.
Across 392 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novartis$821
- Pfizer$517
- UCB SA$402
- AbbVie$373
- Johnson & Johnson$283
- plus $2K from 24 others
Across 443 payments — averaging $8072.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$990K
- UCB SA$587K
- AbbVie$554K
- E.r. Squibb & Sons, L.L.C.$510K
- Janssen Research & Development, LLC$491K
- Pfizer$273K
- plus $171K from 6 others
What the payments were for
- Travel & lodging$2614%
- Food & beverage$6,07795%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 151 | $2,238 |
| Novartis | 45 | $821 |
| Pfizer | 49 | $517 |
| UCB SA | 5 | $402 |
| AbbVie | 19 | $373 |
| Johnson & Johnson(2 entities) | 21 | $283 |
| Bristol Myers Squibb | 19 | $239 |
| E.r. Squibb & Sons, L.L.C. | 15 | $201 |
| AstraZeneca(2 entities) | 8 | $174 |
| Mallinckrodt Enterprises LLC | 10 | $172 |
| Lilly USA, LLC | 5 | $98 |
| Radius Health, Inc. | 4 | $92 |
| GSK | 5 | $88 |
| ANI Pharmaceuticals, Inc. | 2 | $77 |
| Merck | 5 | $75 |
| UCB, Inc. | 3 | $68 |
| Genentech USA, Inc. | 4 | $68 |
| Zimmer Biomet | 2 | $48 |
| Medexus Pharma, Inc. | 3 | $46 |
| Fidia Pharma USA Inc. | 3 | $44 |
| Gilead | 2 | $43 |
| Sanofi | 2 | $40 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Boston Scientific | 2 | $30 |
| Abbott | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Sobi, Inc | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Forte Bio-pharma LLC | 1 | $13 |
| Organon | 1 | $7 |
How this compares
$6,366 in reported general payments places this provider in the 65th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 238 | $1,723,059 |
| RinvoqUpadacitinib | 158 | $1,155,216 |
| Enbrel SureclickEtanercept | 152 | $1,144,586 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 58 | $867,733 |
| RemicadeInfliximab | 168 | $806,349 |
| OrenciaAbatacept/Maltose | 213 | $758,814 |
| BenlystaBelimumab | 237 | $745,584 |
| KrystexxaPegloticase | 11 | $617,221 |
| Simponi AriaGolimumab | 101 | $614,665 |
| ProliaDenosumab | 356 | $588,592 |
| Orencia ClickjectAbatacept | 79 | $442,871 |
| ActemraTocilizumab | 217 | $442,300 |
| Diclofenac Sodium | 1,382 | $345,203 |
| Xeljanz XrTofacitinib Citrate | 50 | $315,261 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 109 | $261,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa, Prolia, Evenity (2 Syringes), Otezla, Enbrel | $2,238 | $1,793,356529 claims |
| AbbVieRinvoq, Humira(Cf), Humira | $373 | $1,580,538222 claims |
| Johnson & JohnsonRemicade, Simponi Aria | $283 | $1,421,013269 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $201 | $758,814213 claims |
| GSKBenlysta | $88 | $745,584237 claims |
| UCB, Inc.Cimzia (2 Pack) | $68 | $249,77640 claims |
| Lilly USA, LLCForteo | $98 | $218,31152 claims |
| PfizerInflectra, Xeljanz | $517 | $183,25248 claims |
| Radius Health, Inc.Tymlos | $92 | $76,91022 claims |
| Medexus Pharma, Inc.Rasuvo | $46 | $74,363134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 808 rheumatology providers in California.
Other rheumatology in la Palma
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.